2 reports of this reaction
1.7% of all UNDECYLENIC ACID reports
#12 most reported adverse reaction
INTENTIONAL DOSE OMISSION is the #12 most commonly reported adverse reaction for UNDECYLENIC ACID, manufactured by Blaine Labs Inc.. There are 2 FDA adverse event reports linking UNDECYLENIC ACID to INTENTIONAL DOSE OMISSION. This represents approximately 1.7% of all 121 adverse event reports for this drug.
Patients taking UNDECYLENIC ACID who experience intentional dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTENTIONAL DOSE OMISSION is a less commonly reported adverse event for UNDECYLENIC ACID, but still significant enough to appear in the safety profile.
In addition to intentional dose omission, the following adverse reactions have been reported for UNDECYLENIC ACID:
The following drugs have also been linked to intentional dose omission in FDA adverse event reports:
INTENTIONAL DOSE OMISSION has been reported as an adverse event in 2 FDA reports for UNDECYLENIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTENTIONAL DOSE OMISSION accounts for approximately 1.7% of all adverse event reports for UNDECYLENIC ACID, making it a notable side effect.
If you experience intentional dose omission while taking UNDECYLENIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.